A multi-center randomized sigle-blind parallel active controll trial to evaluate the efficacy and safety of Ornidazole Vaginal Gel on Bacterial vaginosis

INTERVENTION: Control group:Ornidazole Vaginal Suppository 0.5g, Vaginal medication, qd, 5 days;test group:Ornidazole Vaginal Gel 0.5g, Vaginal medication, q.d, 5 days; CONDITION: Bacterial vaginosis N76.003 PRIMARY OUTCOME: Efficacy on bacteria examinations (3‐7 days after treatment);Comprehensive efficacy (3‐7 days after the treatme); SECONDARY OUTCOME: Clinical efficacy (28±2 days after the treatment);Efficacy on bacteria examinations (28±2 days after treatment);Comprehensive efficacy (28±2 days after the treatm);Clinical efficacy (3‐7 days after the treatment); INCLUSION CRITERIA: 1. Patients in accordance with bacterial vaginosis diagnostic standards; 2. Patients have sexual life and not in menses. Age: 20‐55; 3. Patients with good follow‐up and compliance conditions and should sign the Informed Consent Form; 4. Menstrual laws,away from the next menstrual flow at least 7 days.